In 2023, the sales of systemic hormonal preparations, excluding sex hormones and insulins, in the UK stood at a notable mark before observing predicted growth. The forecast from 2024 to 2028 indicates a gradual upward trend, with sales expected to rise from $761.33 million in 2024 to $791.56 million in 2028, reflecting steady annual increases. Year-on-year variations exhibit a stable growth trajectory, suggesting consistent demand in the market segment.
Future trends to watch for include:
- Potential shifts in healthcare policies influencing hormonal preparations.
- Innovations in pharmaceutical technologies that could alter market dynamics.
- Changes in patient demographics affecting prescription patterns.
